Optimizing Isotretinoin: Clinical Pearls That Change Practice Tomorrow

Isotretinoin is one of the most effective therapies in acne care, but a successful course is not as simple as reaching a number and stopping. In part one of this Acne Awareness Month episode, host Jamie Restivo, PA-C, sits down with John Barbieri, MD, MBA, to talk through treatment endpoints, recurrence, dosing, absorption, and the day-to-day decisions that shape long-term outcomes. 

Dr Barbieri reframes the goal of isotretinoin as long-term remission rather than a guaranteed cure, a distinction that changes how clinicians counsel patients from the beginning. He discusses why cumulative dose still matters, how clinical endpoints can help individualize care, and why getting patients clear for several months may be more meaningful than stopping at a fixed threshold alone. 

The conversation also gets into recurrence in a way that feels useful in practice—who may be at higher risk, recent data on relapse and retrial, and how hormonal therapies may still have a role for select patients after isotretinoin, even when they did not seem to work before. From severe inflammatory presentations to adult female acne patterns, the episode keeps returning to the same clinical truth: treatment plans should be individualized. 

Restivo and Dr Barbieri also spend time on absorption, once-daily dosing, micronized isotretinoin, omega-3 supplementation, antihistamines, and expectation setting that can make a course more tolerable and less frustrating for patients. The result is a practical, thoughtful discussion for clinicians who prescribe isotretinoin often, but still want to do it with more precision, flexibility, and confidence.